StemCell Therapy

Reports Web presents the intelligent report title as Regenerative Medicine Market Covid-19 Impact Global Analysis and Forecasts by product, application and end user. Market is expected to provide several growth opportunities across the globe. The global market for asset performance management, on the basis of architecture, has been segmented into software and services.

Get Sample Copy of this Report at:

https://www.reportsweb.com/inquiry&RW00013543426/sample

Key Players:

Allergan plc, Integra lifesciences, Mimedx Group, Inc., Medtronic plc, Organogenesis Inc., Zimmer Biomet, Acelity L.P. Inc., Nuvasive, Inc., Stryker Corporation, Japan Tissue Engineering Co., Ltd. (Fujifilm Holdings Corporation subsidiary), Osiris Therapeutics, Inc., Vericel Corporation and other predominate and niche players.

The target audience for the report on the market include, Manufactures, Market analysts, Senior executives, Business development managers, Technologists, R&D staff, Distributors, Investors, Governments, Equity research firms, Consultants.

The report provides complete details about the usage and adoption rate of regenerative medicine in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth.

The market report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global market based on type, and end user. It also provides market size and forecast till 2026 for overall Regenerative Medicine market globally.

Ask For Discount:

https://www.reportsweb.com/inquiry&RW00013543426/discount

Report Overview:

Section 1 Regenerative Medicine Product Definition

Section 2 Global Regenerative Medicine Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Regenerative Medicine Shipments

2.2 Global Manufacturer Regenerative Medicine Business Revenue

2.3 Global Regenerative Medicine Market Overview

2.4 COVID-19 Impact on Regenerative Medicine Industry

Section 3 Manufacturer Regenerative Medicine Business Introduction

Section 4 Global Regenerative Medicine Market Segmentation (Region Level)

Section 5 Global Regenerative Medicine Market Segmentation (Product Type Level)

Section 6 Global Regenerative Medicine Market Segmentation (Industry Level)

Section 7 Global Regenerative Medicine Market Segmentation (Channel Level)

Section 8 Regenerative Medicine Market Forecast 2020-2025

Section 9 Regenerative Medicine Segmentation Product Type

Section 10 Regenerative Medicine Segmentation Industry

Section 11 Regenerative Medicine Cost of Production Analysis

Section 12 Conclusion

Know more Exciting offers of Report:

https://www.reportsweb.com/buy&RW00013543426/buy/3500

*If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Contact Info:Name: Sameer JoshiEmail:[emailprotected]Company Name: ReportsWebWebsite: Reportsweb.com

Phone: +1-646-491-9876

About ReportsWeb:

ReportsWeb.com is a one stop shop of Market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

See the article here:
Regenerative Medicine Market | Leading industry players, products and services, Market Size and Trends 2020-2026 - The News Brok

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, announced that the company will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020 at 5:00 p.m. ET.

About ElevateBio

ElevateBio, LLC, is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading academic researchers, medical centers, and corporate partners, ElevateBios team of scientists, drug developers, and company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBios vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and transitional research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.

ElevateBios investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures HC.

ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, please visit http://www.elevate.bio.

Read more here:
ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference - Business Wire

The Global Video collaboration as a Service (VCaaS) Market was valued at USD 4 Billion in the year 2018. The market is expected to grow at a CAGR of 4.38% during 2019-2024, owing to increase in applications of video conferencing solutions among end users such as healthcare organizations, educational institutions and public sectors. Video conferencing has gained huge popularity and adoption among enterprises as a form of business communication.

Thevideo conferencing solutionshelp organizations to achieve desired goals by discussing the strategies and providing trainings over video conferences to enhance the business output. Introduction of web-based technology with fewer complications by the IT sector is further anticipated to propel the market significantly in near future. Further, surging investment towards innovative products, rising consumer demand, declining manufacturing cost, growing number of outlets and increasing research & development by leading service providers is also expected to augment the market growth.

The Final Report will cover the impact analysis of COVID-19 on this industry:

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10094853

A comprehensive research report published by Azoth Analytics in August 2019 aims to present the analysis of Global Video collaboration as a Service (VCaaS) Market. The report presents the analysis of Video collaboration as a Service (VCaaS) Market by Technology Type (Cloud Conferencing, On Premise Conferencing) and by Usage Type (Meetings, Webinars, Trainings). The Global Video collaboration as a Service (VCaaS) Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) and By Country (United States, Germany, China, India) for the historical period of 2017-2018 and the forecast period of 2019-2024.

Views Source Of Related Reports:

Video Collaboration As A Service (VCaaS) MarketCryptocurrency MarketCash Logistics MarketCar Rental MarketRegenerative Medicine Market Online Food Delivery And Takeaway MarketShea Butter MarketCT Scanner MarketVinyl Flooring MarketHigh Temperature Refractory Insulation Material MarketFloating Production System MarketCompounding Pharmacies MarketVascular Stent MarketRobotic Surgery MarketSalmon Market

Scope of the Report

Global Video Collaboration as a Service (VCaaS) Market (Actual Period: 2017-2018, Forecast Period: 2019-2024) Market Sizing, Growth, Forecast Analysis by Technology Type -Cloud Conferencing, On Premise Conferencing Analysis by Usage Type -Meetings, Webinars, Trainings Competitive Landscape Market Share Analysis

Regional Video Collaboration as a Service (VCaaS) Market North America, Europe, Asia Pacific, ROW (Actual Period: 2017-2018, Forecast Period: 2019-2024) Market Sizing, Growth, Forecast Analysis by Technology Type -Cloud Conferencing, On Premise Conferencing Analysis by Usage Type -Meetings, Webinars, Trainings

Country Analysis Video Collaboration as a Service (VCaaS) Market by Value United States, Germany, China, India (Actual Period: 2017-2018, Forecast Period: 2019-2024) Market Sizing, Growth, Forecast Analysis by Technology Type -Cloud Conferencing, On Premise Conferencing Analysis by Usage Type -Meetings, Webinars, Trainings

Other Report Highlights Strategic Recommendations Market Dynamics Trends, Drivers, Challenges Company Analysis Zoom Video Communications, Inc, Cisco WebEx, LogMein, Inc, BlueJeans Network, Intercall

Customization of the Report

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research

Email:[emailprotected]

Phone: +1 313 462 0609

See the rest here:
Video Collaboration As A Service (VCaaS) Market Share, Trend, Opportunity, Affect On Demand By COVID-19 Pandemic And Forecast 2020-2024 - The Daily...

Post COVID-19 Impact on 3D Cell Culture Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following: Long-term and short-term impact of Covid-19 on the market Cascading impact of Covid-19 on 3D Cell Culture Market, due to the impact on its extended ecosystem Understanding the market behavior Pre- and Post-COVID-19 pandemic Strategy suggestions to overcome the negative impact or turn the positive impact into an opportunity Well help you fight this crisis through our business intelligence solutions.

Pre COVID-19 Analysis of 3D Cell Culture Market

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patients own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture organs-on-chips. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

View out Trending Reports with the Impact of COVID-19:https://www.researchdive.com/covid-19-insights

The major 3D Cell Culture manufacturers includeQGel SA, Hrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

See the original post here:
How COVID-19 Pandemic Will Impact on 3D Cell Culture Market Growth and Demand in 2020 and Coming Future? - The Daily Chronicle

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have found a way, in mice and human tissue, to regenerate the cartilage that eases movement between bones.

Loss of this slippery and shock-absorbing tissue layer, called articular cartilage, is responsible for many cases of joint pain and arthritis, which afflicts more than 55 million Americans.

The researchers can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage before it is badly degraded.

Nearly 1 in 4 adult Americans suffer from arthritis, and far more are burdened by joint pain and inflammation generally.

The researchers figured out how to regrow articular cartilage by first causing slight injury to the joint tissue, then using chemical signals to steer the growth of skeletal stem cells as the injuries heal.

Cartilage has practically zero regenerative potential in adulthood, so once its injured or gone, what we can do for patients has been very limited, says co-senior author Charles K.F. Chan, assistant professor of surgery at Stanford Universitys School of Medicine.

Its extremely gratifying to find a way to help the body regrow this important tissue, Chan says.

The work builds on previous research that resulted in isolation of the skeletal stem cell, a self-renewing cell that is also responsible for the production of bone, cartilage and a special type of cell that helps blood cells develop in bone marrow.

Articular cartilage is a complex and specialized tissue that provides a slick and bouncy cushion between bones at the joints. When this cartilage is damaged by trauma, disease, or simply thins with age, bones can rub directly against each other, causing pain and inflammation, which can eventually result in arthritis.

Damaged cartilage can be treated through a technique called microfracture, in which tiny holes are drilled in the surface of a joint. The microfracture technique prompts the body to create new tissue in the joint, but the new tissue is not much like cartilage.

I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

Microfracture results in what is called fibrocartilage, which is really more like scar tissue than natural cartilage, says Chan. It covers the bone and is better than nothing, but it doesnt have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly.

The most recent research arose, in part, through the work of surgeon and lead author Matthew Murphy, a visiting researcher at Stanford who is now at the University of Manchester.

I never felt anyone really understood how microfracture really worked, Murphy says. I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

For a long time, Chan says, people assumed that adult cartilage did not regenerate after injury because the tissue did not have many skeletal stem cells that could be activated. Working in a mouse model, the team documented that microfracture did activate skeletal stem cells. Left to their own devices, however, those activated skeletal stem cells regenerated fibrocartilage in the joint.

But what if the healing process after microfracture could be steered toward development of cartilage and away from fibrocartilage?

The researchers knew that as bone develops, cells must first go through a cartilage stage before turning into bone. They had the idea that they might encourage the skeletal stem cells in the joint to start along a path toward becoming bone, but stop the process at the cartilage stage.

The researchers used a powerful molecule called bone morphogenetic protein 2 (BMP2) to initiate bone formation after microfracture, but then stopped the process midway with a molecule that blocked another signaling molecule important in bone formation, called vascular endothelial growth factor (VEGF).

What we ended up with was cartilage that is made of the same sort of cells as natural cartilage with comparable mechanical properties, unlike the fibrocartilage that we usually get, Chan says. It also restored mobility to osteoarthritic mice and significantly reduced their pain.

As a proof of principle that this might also work in humans, the researchers transferred human tissue into mice that were bred to not reject the tissue, and were able to show that human skeletal stem cells could be steered toward bone development but stopped at the cartilage stage.

The next stage of research is to conduct similar experiments in larger animals before starting human clinical trials. Murphy points out that because of the difficulty in working with very small mouse joints, there might be some improvements to the system they could make as they move into relatively larger joints.

The first human clinical trials might be for people who have arthritis in their fingers and toes. We might start with small joints, and if that works we would move up to larger joints like knees, Murphy says.

Right now, one of the most common surgeries for arthritis in the fingers is to have the bone at the base of the thumb taken out. In such cases we might try this to save the joint, and if it doesnt work we just take out the bone as we would have anyway. Theres a big potential for improvement, and the downside is that we would be back to where we were before.

One advantage of their discovery is that the main components of a potential therapy are approved as safe and effective by the FDA, says co-senior author Michael Longaker, professor of surgery.

BMP2 has already been approved for helping bone heal, and VEGF inhibitors are already used as anti-cancer therapies, he says. This would help speed the approval of any therapy we develop.

Joint replacement surgery has revolutionized how doctors treat arthritis and is very common: By age 80, 1 in 10 people will have a hip replacement and 1 in 20 will have a knee replaced. But such joint replacement is extremely invasive, has a limited lifespan and is performed only after arthritis hits and patients endure lasting pain.

The researchers say they can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage in their joints before it is badly degraded.

One idea is to follow a Jiffy Lube model of cartilage replenishment, Longaker says. You dont wait for damage to accumulateyou go in periodically and use this technique to boost your articular cartilage before you have a problem.

The work appears in the journal Nature Medicine.

Support for the research came from the National Institutes of Health, the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research, and the Arthritis National Research Foundation.

Source: Stanford University

Read the rest here:
Method regrows cartilage to cushion bones - Futurity: Research News

(PRESS RELEASE) PLEASANTON, CA IrisVision, the leader in digital vision technologies, today announced it has partnered with the Seva Foundation to develop new technology that will democratize vision healthcare around the world.

Seva Foundation is a global non-profit organization that provides eye care services to underserved communities across the globe. Since 1978, Seva has provided sight-saving surgeries, medicine and other eye care services to more than 40 million people globally.

In the first phase of this unique public-private partnership, Seva will provide IrisVision with a grant of $200,000 to help create new technologies to treat vision impairment, and even prevent blindness, in less privileged parts of our world. IrisVision, which is best known as the creator of an award-winning VR solution that restores sight for those with vision impairments and is currently developing new telehealth applications for its vision care platform, will contribute its extensive R&D talent, leadership and resources to the initiative.

This partnership with IrisVision will help Seva to continue delivering cutting-edge science and technology in eye health and vision care to the worlds underserved communities, said Seva Executive Director Kate Moynihan. One of our key tenets has been to continue investing in technology that advances eye care for affected and at-risk communities, wherever they may be. When we saw the ground-breaking work IrisVision is already doing in low vision aids, virtual vision diagnostics and remote delivery of eye care, we knew they have the scientific, technical and leadership talent to take our work even further.

According to IrisVision CEO and Co-founder Ammad Khan, Partnering with such a respected and prestigious organization as the Seva Foundation is an honor. They have established the pathways over their 40 years of hard work to restore sight to more than five million people in communities across the globe. In turn, our technology can help these communities regain the life-changing gift of sight. Together, we can truly make a difference in the world.

Here is the original post:
Seva Foundation Partners with IrisVision to Democratize Vision Care Through Innovation - InvisionMag

A new study shows vision loss is almost twice as common among military veterans than among civilians and was independently associated with self-reported illicit drug use.

The results should trigger increased awareness among both behavioral and eye health specialists, study author Justin Tyler McDaniel, PhD, associate professor of Public Health at Southern Illinois University's School of Human Sciences, Carbondale, told Medscape Medical News.

"As behavioral health folks routinely screen for alcohol misuse and drug use, they potentially could do some vision screening and refer folks to an optometrist if necessary," McDaniel said.

Conversely, ophthalmology professionals "perhaps could begin to implement screening for drug use during routine visits for eye checkup," and refer those who screen positive, he said.

The paper was published online August 13 in BMJ Military Health.

Studies have uncovered numerous associations between substance abuse and ocular injuries. For example, some have linked cocaine and methamphetamine with corneal injuries, and others have tied opiates, cocaine, methamphetamine and "bath salts," synthetic recreational stimulants, to iris injuries.

Justin Tyler McDaniel, PhD

Vision impairment has been associated with other health behaviors and conditions as well, the researchers note, including HIV, hypertension, smoking, diabetes, poor diet, physical activity, cancer, depression, gum disease, and socioeconomic status.

The new study aimed to more closely assess these streams of research "to see if there's any association between drug use and vision loss," said McDaniel.

The study included 1578 randomly selected participants (1472 civilians and 106 military service members or veterans) in the 2013 to 2018 cycles of the National Health and Nutrition Examination Survey (NHANES). NHANES is a nationally representative survey of health and nutrition status among US residents.

Since NHANES doesn't interview institutionalized individuals, which would include those in active military service, "we assume that all our sample was veterans," who were retired from active duty and living in the community, said McDaniel.

Survey questions determined use of cocaine, methamphetamine, and heroin, and of injection drug use. In addition to illicit drug use, study covariates included age, gender, race/ethnicity, education level, household income, blood pressure, diabetes, smoking, diet, sedentary time, health insurance, cancer history, depression, HIV status, and oral health.

The dependent variable was self-reported vision loss, which was obtained from the disability module in the NHANES. Respondents were asked if they are blind or have serious difficulty seeing even when wearing glasses.

The analysis showed that compared to civilians, veterans had a significantly higher prevalence of HIV-positive status (1.89% vs 0.41%; P = .038) and illicit drug use (20.75% vs 13.62%; P = .041).

While active military members tend to have lower rates of illicit drug use compared with civilians because of a "zero tolerance" policy and random drug testing, veterans retired from service may be dealing with posttraumatic stress disorder (PTSD) that "may be connected to beginning of illicit drug use," said McDaniel.

The rate of 1 in 5 veterans using illicit drugs seems high, but should be taken in context, said McDaniel, noting that the measure of illicit drug use in the survey is "quite broad."

"It could be someone who chronically uses illicit drugs or someone who just tried it one time," he noted.

More veterans in the study (8.49%) reported vision loss than civilians (4.48%). The higher prevalence of vision loss among veterans could be because of exposure to combat explosions, said McDaniel, but veterans also had more risk factors possibly linked to vision impairment.

For example, they had higher mean values of systolic blood pressure (125.8 vs 122.5 mm Hg), more pack years of cigarette smoking (8.29 vs 4.25), and more sedentary minutes per day (379.15 vs 337.07 min).

On the other hand, civilians had a higher prevalence of poor dietary habits; only 7.61% reported trying the MyPlate diet plan, which highlights elements of a healthy diet, vs 13.21% of veterans (P = .032).

In a model that adjusted for risk factors of vision loss including physical inactivity, diabetes, socioeconomic factors, and other health behaviors and conditions military service status (adjusted coefficient [aB] 0.91; P = .04) and illicit drug use (aB 0.72; P = .02) were associated with increased risk for vision loss. The next strongest predictor was HIV-positive status.

McDaniel stressed that the study shows only an association between drug use and vision loss, without determining from which direction the association is occurring.

"We have no way of inferring causation here," he said. "It could be that vision loss is a stressor that results in drug use, or it could be that a history of drug use leads to vision loss down the road."

McDaniel would like future research projects to determine where in the US veterans are most prone to illicit drug use and to vision loss. "Then we can begin to really refine and target some public health programming in those areas," he said.

"We could then maybe look at screening and brief interventions for service members who use drugs. And for vision loss, we could implement some sort of screening and vision rehabilitation programs."

Commenting on the study for Medscape Medical News, Kate Hendricks Thomas, PhD, from George Mason University's Department of Global and Community Health, Fairfax, Virginia, said the current study is a continuation of McDaniel's "interesting research" on the links between service experiences, behavioral health trends, and health outcomes among active military and veterans.

"The results of the present study are interesting in that they outline key predictor variables' influence on eye health," said Thomas.

"The study does a nice job of demonstrating empirically what we know about risk behaviors in military veterans," that they can lead to poorer health outcomes, said Thomas.

While substance abuse isn't the only behavior that can be correlated to poor eyesight, "in the present study, it demonstrated a strong enough link that screening veterans for addictive behaviors is warranted in the clinical setting."

The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors. McDaniel and Thomas have disclosed no relevant financial relationships.

BMJ Mil Health. Published online August 13, 2020. Abstract

For more Medscape Psychiatry news, join us on Twitter and Facebook

Go here to see the original:
Illicit Drug Use Tied to Vision Loss - Medscape

Sunu Band on wrist

Foresight is wonderful in business but when robotics engineer Marco Trujillo and legally blind chemist and serial entrepreneur Dr. Fernando Albertorio launched the Sunu Band in 2018, they couldnt possibly have imagined the new normal lurking just around the corner.

The Sunu Band is an advanced mobility aid for the blind and severely sight impaired.

Worn like a watch or wristband, the device uses sonar and echolocation to detect objects in the wearers path and then provides haptic vibrations to supply information on proximity. The closer the object, the more frequent the vibrations, which then fade when the object is further away.

During the coronavirus pandemic, maintaining social distancing has been a major challenge for those with severe vision impairments, leaving many fearful of leaving their homes.

In the event that an emergency global hackathon for medical engineers was organized to identify a technological solution to this complex challenge, the device to emerge might well closely resemble the Sunu Band.

Via a paired mobile app, Sunu even allows the user to select the distance at which they wish to be alerted, which ranges from 1.5 to 5 meters.

The band has been likened to a radar or flashlight for those with sight loss, identifying objects when the sensor is angled in their direction. It may also be understood as a form of sense enhancing augmented reality with a tactile overlay, rather than the visual one commonly seen in mainstream AR devices.

As the pandemic wore on, the company began to receive an increasing number of reports from its customers about how helpful the band is for maintaining social distancing.

Social distancing is the use case that all our customers have been telling us about, says Albertorio.

They find it particularly helpful for standing in a queue and being alerted when the person in front is starting to move forward, as well as the avoidance of people and obstacles in the supermarket.

Resembling a Fitbit, the Sunu Band also features a lightweight, cosmetically acceptable form factor, a design challenge that appears to have perpetually dogged manufacturers of low vision wearables.

Sunu Band on Wrist

The device also offers safety benefits by allowing users to operate their smartphone directly through the band, while the phone itself is tucked away snugly.

Sunu Band began life in Guadalajara, Mexico in 2013 after Trujillo undertook a community project at a school for the blind. During this time, he developed a keen interest in the way in which blind children learn to navigate and noted the upper body injuries they often sustain bumping into obstacles.

Trullijos path was to cross with Albertorio a year later when Albertorio was a mentor at the 2014 MassChallenge, a Boston-based global accelerator and competition for innovative start-ups.

The Sunu Band went on to win a Gold Award there and also won the Perkins School for the Blind Technology Sidecar Prize, later winning a Global Elevate Award in 2016.

Prior to its market launch in 2018, Sunu also went through Y Combinator, a highly competitive Silicon Valley-based accelerator program.

Albertorio joined up with the fledgling company, not just as a serial tech entrepreneur but in his capacity as a legally blind individual.

He has albinism, which, in his case, results in severe light sensitivity and eye movement disorders.

The band is not envisaged as a replacement for a white cane or a guide dog but as an additional novel layer of sense enhancement.

The original use case considered was the avoidance of raised or overhead obstacles, anything not being picked up by a regular sweep of the cane.

Chris McNally, a low vision technology enthusiast, who was born with a form of Retinitis pigmentosa that severely impairs his ability to see in low light, is a dedicated user of the device and offers up some fascinating insights on how the band has remapped his senses.

When navigating, it feels like my brain has been so starved of information that when something new and useful is incorporated, it latches right on to it, he says.

Feedback from the band is now integrated so deeply into the way I move around; Im not even consciously thinking about the new input coming in anymore.

As I sweep back and forth, he continues, Im sensing walls and doorways. If I feel it pulsing faster, I know its a person coming at me, which is awesome, particularly because of the situation with Covid.

This sense enhancing aspect is something which Katrina Best, an Orientation and Mobility Specialist based in Collier County, Florida working with school children and adults living with sight loss has also noted.

I was working with a client in his fifties who is now totally blind and I wanted to try out the Sunu Band with him, she says.

We walked to a restaurant and I put it on him and he chuckled because he could suddenly tell when the waitress was walking past and ignoring us. The wearer can really feel when people are walking around them.

I feel like its a tool for independence, she continues. Too often, students I see in grade schools and older adults tend to just rely on others.

In terms of a future pipeline, the interoperability of the hardware with a dedicated smartphone app means the opportunities to expand functionality are limitless.

This may include more granular mapping and guidance for blind people, even down to a street furniture level, and as a platform technology, further integration with third-party apps, such as Be My Eyes or even Uber.

As a company, we want to challenge certain societal perceptions where people with disabilities are viewed as helpless, says Albertorio.

We believe wearable technologies that can augment human abilities have a big role to play in creating equity for disabled people through bridging the information gap and empowering and enhancing the senses.

Over the socially distanced shorter term, the company is exploring other use cases for the Sunu Band. This could include individuals with suppressed immune systems seeking an extra level of protection when out and about.

There may also be mainstream applications for employees wishing to monitor distancing in closed or crowded working environments, such as in the hospitality sector, or for certain leisure activities where vision is reduced, like caving.

The Sunu Band may not quite yet feature all the bells and whistles of the Apple Watch but priced at $299 (three quarters of the price of the tech giants device), it offers those who could benefit so much more.

After all, innovative assistive technology devices are more than just cool gadgets to enjoy. They hack the human operating system at a fundamental level and can, thereby, promote unique and personalized modalities for independence.

Excerpt from:
Sunu Band The Smart Wearable Helping Blind People Maintain Social Distance - Forbes

Report is a detailed study of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is to help making reliable strategic decisions regarding the opportunities in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. It offers business accounts, industry investors, and industry segments with consequential insights enhancing decision making ability.[emailprotected] or call us on +1-312-376-8303.

Request Report from CMR Website:https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report

Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segmentation by Type: Platelet Rich Plasma Injections, Stem Cell Therapy

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segmentation by Applications: Dermatology Clinics, Hospitals

Major Market Players with an in-depth analysis: Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute

Request Free Sample Copy of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research [emailprotected] https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#download_report

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report offers the current state of the market around the world. The report starts with the market outline and key components of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies business and market elements.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report 2020 (Coronavirus Impact Analysis on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market)

The research comprises primary information about the products. Similarly, it includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. Additionally, report provides market drivers and challenges & opportunities for overall market in the particular provincial sections.

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies product has been completely profiled along with their SWOT. Some of the key players include Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

DOWNLOAD FREE SAMPLE [emailprotected]: https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#download_report

Chapters Define in TOC (Table of Content) of the Report:Chapter 1: Market Overview, Drivers, Restraints and Opportunities, SegmentationOverviewChapter 2: COVID ImpactChapter 3: Market Competition by ManufacturersChapter 4: Production by RegionsChapter 5: Consumption by RegionsChapter 6: Production, By Types, Revenue and Market share by TypesChapter 7: Consumption, By Applications, Market share (%) and Growth Rate byApplicationsChapter 8: Complete profiling and analysis of ManufacturersChapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wiseManufacturing expensesChapter 10: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 11: Marketing Strategy Analysis, Distributors/TradersChapter 12: Market Effect Factors AnalysisChapter 13: Market ForecastChapter 14: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Research Findings and Conclusion, Appendix, methodology and data source To check the complete Table of Content click here: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#table_of_contents

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2027.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients.

Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report

Go here to read the rest:
Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research Study 2020 Insights with COVID-19 Impact Analysis by 2020Orange...

MarketsandResearch.biz has published the latest market research study on Global Cell Isolation Technology Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which investigates a few critical features of the market such as industry condition, division examination, market insights. The report studies the global Cell Isolation Technology market share, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels. The report has referenced down to earth ideas of the market in a straightforward and unassuming way in this report. The research contains the categorization of the market by top players/brands, region, type, and end-user. The report exhaustive essential investigation of current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The research report has comprehensively included numbers and figures with the help of graphical and pictorial representation which embodies more clarity on the global Cell Isolation Technology market. Then the report delivers key information about market players such as company overview, total revenue (financials), market potential, global presence, as well as market share, prices, production sites and facilities, products offered, and strategies adopted by them. Market status and outlook of global and major regions, from angles of players, countries, product types, and end industries have been analyzed.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/82010

Key strategic manufacturers included in this report: Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Merck, Stemcell Technologies, BD Biosciences, GE Healthcare, Terumo BCT

Market Potential:

Key market vendors have been predicted to obtain the latest opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. Also, many of the market contenders are forecasted to make a foray into the emerging economies to find new opportunities. The global Cell Isolation Technology market has gone through rapid business transformation by good customer relationships, drastic and competitive growth, significant changes within the market, and technological advancement in this market.

Geographically, this report is segmented into several key countries, with market size, growth rate, import and export of in these countries from 2015 to 2020, which covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

The market can be segmented into product types as: Centrifugation, Flow Cytometry, Cell Electrophoresis

The market can be segmented into applications as: Stem cell research, Cancer research, Tissue regeneration, In-vitro diagnostics, Others

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/82010/global-cell-isolation-technology-market-2020-by-company-regions-type-and-application-forecast-to-2025

Reasons for Buying Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Visit link:
Global Cell Isolation Technology Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - Scientect

In 2029, the Suramin Sodium market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Suramin Sodium market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Suramin Sodium market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Suramin Sodium market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2769976&source=atm

Global Suramin Sodium market report on the basis of market players

The report examines each Suramin Sodium market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Suramin Sodium market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Segment by Type, the Suramin Sodium market is segmented intoTabletCapsule

Segment by Application, the Suramin Sodium market is segmented intoAntitumor DrugAntiviral DrugsImmunomodulator

Regional and Country-level AnalysisThe Suramin Sodium market is analysed and market size information is provided by regions (countries).The key regions covered in the Suramin Sodium market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Suramin Sodium Market Share AnalysisSuramin Sodium market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Suramin Sodium business, the date to enter into the Suramin Sodium market, Suramin Sodium product introduction, recent developments, etc.

The major vendors covered:MP BiomedicalsBOC ScienceVWRSigma-AldrichCayman ChemicalStemcell Technologies

Report available at a discounted price exclusively!!! Offer ends today!!!

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2769976&source=atm

The Suramin Sodium market report answers the following queries:

The Suramin Sodium market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2769976&licType=S&source=atm

Research Methodology of Suramin Sodium Market Report

The global Suramin Sodium market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Suramin Sodium market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Suramin Sodium market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

See the article here:
Suramin Sodium Market Projected to Witness a Single-Digit CAGR During 2019-2025 - StartupNG

This article was originally published here

J Med Internet Res. 2020 Aug 28;22(8):e21778. doi: 10.2196/21778.

ABSTRACT

BACKGROUND: The Onduo virtual diabetes clinic (VDC) for people with type 2 diabetes (T2D) combines a mobile app, remote personalized lifestyle coaching, connected devices, and live video consultations with board-certified endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices for intermittent use.

OBJECTIVE: This prospective single-arm study evaluated glycemic outcomes associated with participation in the Onduo VDC for 4 months.

METHODS: Adults aged 18 years with T2D and a baseline glycated hemoglobin (HbA1c) of 8% to 12% were enrolled from 2 primary care centers from February 2019 to October 2019. Participants were asked to engage at 1 time per week with their care team and to participate in a telemedicine consultation with a clinic endocrinologist for diabetes medication review. Participants were asked to use a RT-CGM device and wear six 10-day sensors (total 60 days of sensor wear) intermittently over the course of 4 months. The primary outcome was change in HbA1c at 4 months from baseline. Other endpoints included change in weight and in RT-CGM glycemic metrics, including percent time <70, 70-180, 181-250, and >250 mg/dL. Changes in blood pressure and serum lipids at 4 months were also evaluated.

RESULTS: Participants (n=55) were 57.3 (SD 11.6) years of age, body mass index 33.7 (SD 7.2), and 40% (22/55) female. HbA1c decreased significantly by 1.6% (SD 1%; P<.001). When stratified by baseline HbA1c of 8.0% to 9.0% (n=36) and >9.0% (n=19), HbA1c decreased by 1.2% (SD 0.6%; P<.001) and 2.4% (SD 1.3%; P<.001), respectively. Continuous glucose monitoring-measured (n=43) percent time in range (TIR) 70-180 mg/dL increased by 10.2% (SD 20.5%; P=.002), from 65.4% (SD 23.2%) to 75.5% (SD 22.7%), which was equivalent to a mean increase of 2.4 hours TIR per day. Percent time 181-250 mg/dL and >250 mg/dL decreased by 7.2% (SD 15.4; P=.005) and 3.0% (SD 9.4; P=.01), respectively. There was no change in percent time <70 mg/dL. Mean weight decreased by 9.0 lb (SD 10.4; P<.001). Significant improvements were also observed in systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, and triglycerides (P=.04 to P=<.001).

CONCLUSIONS: Participants in the Onduo VDC experienced significant improvement in HbA1c, increased TIR, decreased time in hyperglycemia, and no increase in hypoglycemia at 4 months. Improvements in other metabolic health parameters including weight and blood pressure were also observed. In conclusion, the Onduo VDC has potential to support people with T2D and their clinicians between office visits by increasing access to specialty care and advanced diabetes technology including RT-CGM.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381.

PMID:32856597 | DOI:10.2196/21778

See the original post here:
Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor-Driven Virtual Diabetes Clinic: Prospective Trial -...

An increase in the use of preventive medication for diabetes may reduce the risk of heart attacks in patients. This is the finding of a research study presented today at the ESC Congress 2020.

Our results suggest that when patients are diagnosed with type 2 diabetes, starting medications to prevent cardiovascular disease has a substantial impact on the risk of heart attacks and premature death, said principal investigator Dr Christine Gyldenkerne of Aarhus University Hospital, Denmark.

People with type 2 diabetes are twice as likely to have a heart attack or die from heart disease compared to people without diabetes.

Management of patients with type 2 diabetes has changed considerably over the last two decades, with an increased focus on the prevention of cardiovascular disease. This was the first study to examine how these changes may have affected the risk of heart attacks and premature death in patients with newly diagnosed type 2 diabetes and no previous cardiovascular disease.

The researchers identified all patients in Denmark initiating therapy for type 2 diabetes from 1996 to 2011-- a total of 211,278 patients. Each patient with diabetes was matched on age and sex with five people without diabetes from the general population. Those with previous cardiovascular disease were excluded.

All participants were followed for seven years. Using data from national health registries, the researchers recorded heart attacks and death during follow-up. They also noted the use of medications to prevent cardiovascular disease at the time of diabetes diagnosis.

The researchers found that patients with newly diagnosed type 2 diabetes and no previous cardiovascular disease experienced major reductions in the risk of heart attack and death. From 1996 to 2011, the relative risk was reduced by 61% for heart attack and by 41% for death. During the same period, the absolute risks of heart attack and death reduced by 4% and 12%, respectively.

When comparing patients with diabetes to the general population, the initially large differences in risk narrowed over time. By the end of the study, the risk of heart attack among patients with diabetes was only marginally-- 0.6%-- higher than in the general population.

In those with diabetes, use of cholesterol-lowering medications increased more than 10-fold, aspirin increased by 50%, and blood pressure-lowering medications increased up to four times during the study period.

Dr Gyldenkerne said: The risk of heart attack and premature death among patients with newly diagnosed type 2 diabetes and no previous cardiovascular disease was approximately halved from 1996 to 2011. In the same period, the difference in risk of heart attack and death for patients with diabetes, as compared to the general population, was narrowed substantially.

She noted that this was an observational study and causation cannot be assumed. Dr Gyldenkerne said: In addition to the use of preventive medications, other factors may have influenced the likelihood of heart attack and premature death. For example, stricter control of diabetes and lifestyle changes such as smoking cessation, physical activity, and healthier food may have contributed to the improved prognosis.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Follow more stories on Facebook and Twitter

The rest is here:
Heres what patients with diabetes should do to reduce risk of heart attacks - Hindustan Times

An increase in the use of preventive medication for diabetes may reduce the risk of heart attacks in patients. This is the finding of a research study presented today at the ESC Congress 2020. "Our results suggest that when patients are diagnosed with type 2 diabetes, starting medications to prevent cardiovascular disease has a substantial impact on the risk of heart attacks and premature death," said principal investigator Dr Christine Gyldenkerne of Aarhus University Hospital, Denmark.

People with type 2 diabetes are twice as likely to have a heart attack or die from heart disease compared to people without diabetes. Management of patients with type 2 diabetes has changed considerably over the last two decades, with an increased focus on the prevention of cardiovascular disease. This was the first study to examine how these changes may have affected the risk of heart attacks and premature death in patients with newly diagnosed type 2 diabetes and no previous cardiovascular disease.

The researchers identified all patients in Denmark initiating therapy for type 2 diabetes from 1996 to 2011-- a total of 211,278 patients. Each patient with diabetes was matched on age and sex with five people without diabetes from the general population. Those with previous cardiovascular disease were excluded. All participants were followed for seven years. Using data from national health registries, the researchers recorded heart attacks and death during follow-up. They also noted the use of medications to prevent cardiovascular disease at the time of diabetes diagnosis.

The researchers found that patients with newly diagnosed type 2 diabetes and no previous cardiovascular disease experienced major reductions in the risk of heart attack and death. From 1996 to 2011, the relative risk was reduced by 61% for heart attack and by 41% for death. During the same period, the absolute risks of heart attack and death reduced by 4% and 12%, respectively. When comparing patients with diabetes to the general population, the initially large differences in risk narrowed over time. By the end of the study, the risk of heart attack among patients with diabetes was only marginally-- 0.6%-- higher than in the general population.

In those with diabetes, use of cholesterol-lowering medications increased more than 10-fold, aspirin increased by 50%, and blood pressure-lowering medications increased up to four times during the study period. Dr Gyldenkerne said: "The risk of heart attack and premature death among patients with newly diagnosed type 2 diabetes and no previous cardiovascular disease was approximately halved from 1996 to 2011. In the same period, the difference in risk of heart attack and death for patients with diabetes, as compared to the general population, was narrowed substantially."

She noted that this was an observational study and causation cannot be assumed. Dr Gyldenkerne said: "In addition to the use of preventive medications, other factors may have influenced the likelihood of heart attack and premature death. For example, stricter control of diabetes and lifestyle changes such as smoking cessation, physical activity, and healthier food may have contributed to the improved prognosis." (ANI)

Go here to see the original:
Increase in medication for diabetes may reduce risk of heart attacks, suggests study - Devdiscourse

Prompted by a ProPublica story that detailed how Black Americans with diabetes lose limbs at a rate triple that of others, the American Diabetes Association has included an initiative to prevent unnecessary amputations as part of an unprecedented campaign to reduce racial disparities in diabetes care.

"The ProPublica article raised the consciousness of what the problem is," said Tracey Brown, the CEO of the ADA. "Every four minutes, someone is losing a limb from diabetic complications. That's ridiculous. We have got to find a way to drive change."

The story highlighted obstacles to equitable care for diabetic patients at risk of amputation, from the government's decision not to endorse screening at-risk patients for vascular disease in the legs, to the inadequate incentives for certain specialists to move to underserved areas, to the health system's failure to consider limb-saving options before permitting surgeons to apply a blade.

In the weeks that followed publication, several congressional and state legislative offices reached out to the association to ask for guidance on drafting policy to reduce disparities in diabetic amputations. In response, the organization decided to build an agenda around the issue.

The ADA's Health Equity Now campaign, which addresses the cost of diabetes care, nutrition, discrimination and more, was motivated by the racial health disparities that have been exposed by COVID-19, which has hit Black Americans with diabetes particularly hard. As part of the project, the association has built a Health Equity Bill of Rights, asserting that all diabetes patients are entitled to affordable drugs, healthy food, the latest medical advances and other protections.

The right to avoid preventable amputations is the only complication of uncontrolled diabetes that is included in the list. The organization is sharing the document with policymakers, practitioners and patients as it begins to look toward policy change. It is also encouraging members of the public to ask their governors to support the project.

Dr. Ronald Dalman, the president of the Society for Vascular Surgery, said: "I commend the ADA for doubling down on this particular complication of poorly managed diabetes. It's a long overdue prioritization." He added that it's a "moment in time where we can leverage this concern about health care disparities to call out a very specific problem: the prevalence of amputation in certain subsets of the population."

Dr. Gary Puckrein, the head of the National Minority Quality Forum, a nonprofit focused on reducing health care disparities, said that the ADA's efforts are just a step. "The American health care system was organized during an era when inequality was acceptable and mainstream in American society," he said. "It's not that African Americans are sicker, it's that the health care delivered is unequal."

He hopes that the national conversation on health disparities will mirror the conversation about police violence against Black Americans. "You, in effect, have your knees on their neck in the health care system as well when you don't provide them with the care that they need."

Two weeks after publication of the story, Rep. Bennie Thompson, a Democrat from Mississippi, honored Dr. Foluso Fakorede, the main subject of the ProPublica article, for his work in reducing unnecessary amputations in Bolivar County, Mississippi. The acknowledgement, made in the House of Representatives, referenced ProPublica's findings.

The co-chairs of the Congressional Peripheral Artery Disease Caucus Rep. Donald M. Payne Jr., a Democrat from New Jersey, and Rep. Gus Bilirakis, a Republican from Florida have also begun work on a bill to address disparities in amputations, particularly for people with peripheral artery disease, a condition in which clogged arteries in the legs limit the flow of blood.

"The ProPublica article has brought strong awareness and real interest from a variety of parties from the medical field and from patients and from potentially future patients," said a spokesman for Payne. "We have been working with Bilirakis and other members to move this forward, with the ultimate goal of introducing legislation."

Summer Blevins, deputy chief of staff for Bilirakis, added that their legislative ambition "is based on the basic principle that prevention, education and early intervention is best for the patient and also saves money."

Lizzie Presser covers health, inequality and how policy is experienced for ProPublica.

More:
Blacks With Diabetes Lose Limbs at 3x the Rate of Others - Medscape

This article was originally published here

Diabetes Res Clin Pract. 2020 Aug 25:108393. doi: 10.1016/j.diabres.2020.108393. Online ahead of print.

ABSTRACT

BACKGROUND AND AIM: Jordan implemented abrupt and extreme lockdown measures to prevent the spread of COVID-19. This study aims to evaluate the effect of these measures on paediatric patients with type 1 diabetes in terms of acute metabolic complications and shortages in insulin and glucose measuring supplies. It also evaluates the caregivers perceptions of the use of telemedicine during the lockdown.

METHODS: This is a questionnaire-based cross-sectional study. It was completed using Google forms and patients / caregivers were asked to consent if they agreed to answer.

RESULTS: 235 patients/families participated in the study. The mean age of the patients was 10.8 years 3.9 years (N=229). Twenty-four children (10.2%) needed to visit the emergency department during the lockdown period which lasted for 10 weeks. Of these, eight (3.4%) were hospitalized due to acute metabolic complications. Families (58.3 %) faced insulin shortages and 14% had to ration insulin, i.e., decrease the dose, during the lockdown. Glucose monitoring strips were rationed by 43.4% of families leading to more frequent low / high glucose readings in 75.5% of children of these families. Telemedicine using phones and social media applications was utilized for communication with healthcare professionals and continuing medical care. Most of the participants (85.5 %) described it as a smooth and positive experience.

CONCLUSIONS: The extreme lockdown due to COVID-19 pandemic caused insulin and glucose measuring equipment shortages in children with diabetes in Jordan. However, the use of telemedicine for providing guidance and support was perceived positively by the families.

PMID:32858098 | PMC:PMC7446666 | DOI:10.1016/j.diabres.2020.108393

Continued here:
Caring for a Child with Type 1 Diabetes During COVID-19 lockdown in a developing country: Challenges and Parents' Perspectives on the Use of...

This article was originally published here

J Epidemiol Community Health. 2020 Aug 27:jech-2020-214267. doi: 10.1136/jech-2020-214267. Online ahead of print.

ABSTRACT

BACKGROUND: To evaluate regional disparities in the influence of diabetes on population health, we examine life expectancies at age 50 between population with diabetes and healthy population and life quality among the population with diabetes among native-born Americans by birth region and current residence.

METHODS: Using data on a cohort of 17 686 native-born individuals from the Health and Retirement Survey (1998-2014), we applied a Bayesian multistate life table method to estimate life expectancies at age 50 between population with diabetes and healthy population by each birth/current region combination. We further estimate the proportion of life remaining without either chronic conditions or disabilities as a quality of life measure and the probabilities that one region is worse than the other in terms of different health outcomes.

RESULTS: At age 50, persons with diabetes (PWD) were expected to live on average 5.8-10.8 years less than their healthy equivalents across regions. Diabetes had the greatest influence on life expectancy (LE) for older adults who lived in the South at the time of interviews. PWD born in the South were more likely to have developed chronic conditions or disabilities and spent greater proportions of life with these two issues compared to other regions.

CONCLUSION: Diabetes is a significant threat to LE and healthy LE in the USA, particularly for people born or living in the South.

PMID:32855262 | DOI:10.1136/jech-2020-214267

Read the rest here:
Regional differences in the impact of diabetes on population health in the USA - DocWire News

Become a scientist of yourself by studying how foods affect your blood sugars. There are charts that can help you figure out the sugar toxicity, like the Glycemic Index. Also, take into consideration the glycemic load of foods. The Glycemic Index gives specific foods a 0-100 rating on how much it will make blood sugar rise. The higher the number, the more potent the food will be to your blood sugar.

Glycemic load will take the information of the Glycemic Index and add the amount of grams you will be eating, then divide it by the amount of portions you consume. This isnt a perfect system. Everyone processes food differently. In other words, what works for one person may not work for another. Discover for yourself how each meal affects you and start dialing in what foods are beneficial and which ones you should avoid in general.

Increase the amount of exercise you are doing daily. The more muscle mass you have the more sugar you will burn off. Exercise decreases insulin resistance and helps with the overall regulation of sugar throughout the body. When you use your muscles it creates an insulin-like effect, which reduces the need for insulin in general.

This is a very good thing for those with diabetes, because insulin is the problem. If insulin can be bypassed all together, why wouldnt you move more? When you increase your exercise, you will want to continue to monitor your sugar levels and make sure to have a diabetic-friendly snack available if levels get too low.

The rest is here:
Fight diabetes with real foods and exercise - The Daily Nonpareil

Irvine, Calif., Aug. 25, 2020 A new study finds women with diabetes and significant levels of calcium in their coronary arteries have higher rates of death from cardiovascular disease and all causes than their male counterparts.

Published in the American Diabetes Association journal,Diabetes Care,researchers from the University of California, Irvine School of Medicine and Cedars-Sinai Medical Center compared the sex-specific impact of coronary artery calcium (CAC) levels in adults with diabetes.CAC was used to predict cardiovascular and all-cause mortality in patients with diabetes. The results of this comparison showed greater CAC predicts cardiovascular and total mortality more strongly in women.

We showed that coronary calcium scores of greater than 100 in a woman with diabetes was associated with higher death rates from cardiovascular diseases and all causes than similar calcium scores in women than in man with diabetes, saidNathan D.Wong, PhD, professor and director for UCIs Heart Disease Prevention Program, and the lead author for the study.

Wongand colleagues studied 4,503 adults with diabetes from a national registry of patients who received coronary calcium heart scans from computed tomography and were followed for causes of death over more than 11 years. Death rates from cardiovascular disease in those who had coronary calcium scores of 101-400 or more, were approximately twice as high in women compared to men. Total death rates in these patients were also higher in women than in men. In analyses adjusted for age and other potential confounders, compared to those with calcium scores of 0, women who had calcium scores of 101-400 and 401 or greater had cardiovascular deaths that were 3.7 and 6.3-fold greater, respectively, compared to men whose risks were 1.6 and 3.5-fold greater, respectively.

Our findings, showing significant levels of coronary calcium to predict mortality from cardiovascular causes more strongly in women than men with diabetes, might also help to explain the poorer prognosis for cardiovascular disease that has been observed for decades in women compared to men with diabetes, saidWong.

Conversely, very low death rates from coronary heart disease and cardiovascular disease seen in those with diabetes who had negative scans (calcium scores of 0), comprising 39 percent of women and 20 percent of men in our study, underscore the point that not all persons with diabetes are risk equivalents for cardiovascular disease, as has been the common belief for decades, noted Cedars-Sinai Medical CentersDaniel Berman, MD, senior author of the study.

Our findings suggest a call-to-action for even more aggressive risk factor management in a woman with diabetes found to have significant levels of coronary calcium to prevent future death from cardiovascular causes saidWong. Previous research conducted byWongand colleagues, has shown rates of cardiovascular disease to be 60 percent lower in those who are well-controlled for blood sugar, cholesterol, and blood pressure.

The study population was part of the CAC Consortium, directed byMichael Joseph Blaha, MD, MPH, from Johns Hopkins School of Medicine. UCIs Amber Cordola-Hsu, PhD, co-led the study withWong.

This study was funded in part by the National Institutes of Health and the American Heart Association.

About the UCI School of Medicine: Each year, the UCI School of Medicine educates more than 400 medical students, and nearly 150 doctoral and masters students. More than 700 residents and fellows are trained at UCI Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visitsom.uci.edu.

About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 222 degree programs. It is located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit http://www.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit news.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.

Here is the original post:
Women with diabetes and high levels of coronary artery calcium at greater risk of death than men - UCI News

Diabetes: Your diet play an important role in maintaining healthy blood sugar levels

Diabetes is a progressive condition and chronic condition which requires constant management of blood sugar levels. If diagnosed early, the progression can be slowed considerably with therapeutic diet and physical activity. But if left uncontrolled, the blood sugar levels may start affecting different organs of the body. It is advised that diabetics should keep a constant check on the blood sugar levels and follow all necessary precautions to avoid major fluctuations.

Physical activity helps in controlling progression of the condition. But what is not clear is the ideal dietary pattern to be followed. There is a lot of uncertainty in nutrition claims, what was true yesterday may have some other aspects to reconsider with emerging research studies. One such research is about how effective is a plant-based diet in managing diabetes. In this article, Mrs. Sweedal Trinidade who is anutritionist and senior dietetics officer at P.D. Hinduja National Hospital explains in detail the pros and cons of a plant-based diet and its effect on diabetes.

A plant-based diet focuses more on eating legumes, whole grains, vegetables, fruits, nuts, and seeds with little or no animal products.

1) No additives: Plant-based diets are minimally or not processed. So, no additives may contribute to insulin resistance.

2)Fibre: Plant-based diets are rich in cellulose and hemicellulose. Both are majorly responsible for maintaining glycemic index of the meals and improving postprandial blood sugar levels.

3) Probiotics: More commonly known as food for gut-friendly bacteria. They are the type of fibre, found in fruits, vegetables and legumes are fermented by intestinal bacteria to produce short-chain fatty acids, which also improve sugar metabolism by increasing insulin sensitivity.

4) Antioxidant-rich: Plant-based diets are usually rich in various antioxidants like-

a) Polyphenols that inhibit glucose absorption and stimulate insulin secretion

b) Magnesium promotes insulin sensitivity thereby improving sugar metabolism

Also read:Diabetes Diet: Know How Many Almonds You Should Eat To Lower Blood Sugar Levels

Diabetes diet: A healthy diet can help in controlling blood sugar levelsPhoto Credit: iStock

Glycaemic index and glycaemic load of food: Plant-based diets are rich in fibre thereby improving satiety, reducing calorie density of meals. They maintain the glycaemic index of the foods and reduce glycemic load of the meals. A perfect balance can help in improving blood sugars considerably.

Also read:Diabetes: Exercise Tips To Manage Blood Sugar Levels; Benefits Of Exercising For Diabetics

Now the question is why India is known as diabetes capital when the diet followed is predominantly vegetarian? This makes it important to highlight the downside of plant-based diet:

In case you decide to rely completely on plant-based diet a lot of thought has to go in planning and balancing the diet or else you will land up in the following:

1) Plant-based diets are loaded with carbs usually: This may affect blood sugars.

2) Less of complex carbohydrates and more of simple sugars: This will greatly impact the glycemic load of meals and ultimately the blood sugar levels.

3) Proteins deficiency: If the diet is not planned properly you may miss out on essential amino acids and also land up consuming protein-deficient diet. Hence having foods in right combination can compensate for this. Example right combination of cereals and pulses might help.

Many following plant based diet suffer from protein deficiencyPhoto Credit: iStock

4) Vitamins and minerals: Calcium and iron, no doubt many vegetables are rich in minerals like iron and calcium but due to presence of phytates, oxalates and fiber the bioavailability is low.

5) Vitamin B12: Plant diets are deficient in vitamin B12. Hence it is important to include foods fortified in Vitamin B12.

Also read:5 Nuts And Seeds Loaded With Omega-3 Fatty Acids You Must Add To Your Plant-Based Diet

It is very important to analyse the pros and cons before adopting any diet. Finally, striking the right balance and ensuring no nutritional deficiencies can not only promote good health but also optimal glycemic control!

(Mrs. Sweedal Trinidade, Senior Dietetics Officer, Dietary Services, P.D. Hinduja National Hospital and MRC, Mumbai)

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Originally posted here:
Diabetes: Can A Plant Based Diet Help Control Blood Sugar Levels? Nutritionist Shares The Pros And Cons Of This Diet - NDTV